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Abstract
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed 
to evaluate the safety of live, recombinant viral vaccines incorporating genes from heterologous 
viruses inserted into the backbone of another virus (so-called “chimeric virus vaccines”). Many 
viral vector vaccines are in advanced clinical trials. The first such vaccine to be approved for 
marketing (to date in Australia, Thailand, Malaysia, and the Philippines) is a vaccine against the 
flavivirus Japanese encephalitis (JE), which employs a licensed vaccine (yellow fever 17D) as a 
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vector. In this vaccine, two envelope proteins (prM-E) of YF 17D virus were replaced by the 
corresponding genes of JE virus, with additional attenuating mutations incorporated into the JE 
gene inserts. Similar vaccines have been constructed by inserting prM-E genes of dengue and 
West Nile into YF 17D virus and are in late stage clinical studies. The dengue vaccine is, 
however, more complex in that it requires a mixture of four live vectors each expressing one of the 
four dengue serotypes. This vaccine has been evaluated in multiple clinical trials. No significant 
safety concerns have been found. The Phase 3 trials met their endpoints in terms of overall 
reduction of confirmed dengue fever, and, most importantly a significant reduction in severe 
dengue and hospitalization due to dengue. However, based on results that have been published so 
far, efficacy in preventing serotype 2 infection is less than that for the other three serotypes. In the 
development of these chimeric vaccines, an important series of comparative studies of safety and 
efficacy were made using the parental YF 17D vaccine virus as a benchmark. In this paper, we use 
a standardized template describing the key characteristics of the novel flavivirus vaccine vectors, 
in comparison to the parental YF 17D vaccine. The template facilitates scientific discourse among 
key stakeholders by increasing the transparency and comparability of information. The Brighton 
Collaboration V3SWG template may also be useful as a guide to the evaluation of other 
recombinant viral vector vaccines.
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1. Preamble
1.1. Need for working group and development of a standardized template for collection of 
key information for risk/benefit assessment of viral vector vaccines
Recombinant viral vectors provide an effective means for heterologous antigen expression in 
vivo and thus represent promising platforms for developing novel vaccines against human 
pathogens such as Ebola, human immunodeficiency virus (HIV), tuberculosis, and malaria)
(1–9). Preclinical evaluation of such viral vector vaccines has indicated their potential for 
immunization and an increasing number of candidate vaccines are entering human clinical 
trials. Improving our ability to anticipate potential safety issues and meaningfully assess or 
interpret safety data from trials of such new viral vector vaccines will increase the likelihood 
of public acceptance should they be licensed(10–13).
The Brighton Collaboration (www.brightoncollaboration.org) was formed in 2000 as an 
international voluntary collaboration to enhance the science of vaccine safety research [e.g., 
via development of standardized case definitions of adverse events following immunizations 
(AEFI)] (14). In recognition of these needs in this domain, the Brighton Collaboration 
created the Viral Vector Vaccines Safety Working Group (V3SWG) in October 2008. 
Analogous to the value embodied in standardized case definitions for AEFI, the V3SWG 
believes a standardized template describing the key characteristics of a novel vaccine vector, 
when completed and maintained with the latest research, will facilitate scientific discourse 
among key stakeholders by increasing the transparency and comparability of information. 
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Fortunately, the International AIDS Vaccine Initiative (IAVI) had already developed an 
internal tool to assess the risk/benefit of different viral vectors under its sponsorship. The 
IAVI graciously shared this tool with the V3SWG for adaptation and broader use as a 
standardized template for collection of key information for risk/benefit assessment on any 
viral vector vaccines. This tool was aimed at identifying potential major hurdles or concerns 
that would need to be addressed during the development of a vectored vaccine. The template 
collects information on the characteristics of the wild type virus from which the vector was 
derived as well as known effects of the proposed vaccine vector in animals and humans, 
manufacturing features, toxicology and potency, nonclinical studies, and human use, with an 
overall adverse effect and risk assessment.
The V3SWG hopes that eventually all developers/researchers of viral vector vaccines 
(especially those likely to be used in humans in the near future) will complete this template 
and submit it to the V3SWG and Brighton Collaboration for peer review and eventual 
publication in Vaccine. Following this, to promote transparency, the template will be posted 
and maintained on the Brighton Collaboration website for use/reference by various 
stakeholders. Furthermore, recognizing the rapid pace of new scientific developments in this 
domain (relative to AEFI case definitions), we hope to maintain these completed templates 
“wiki-“ style with the help of Brighton Collaboration and each vector vaccine “community.”
1.2. Need for Risk/Benefit Assessment of Live Virus Vaccines based upon a Yellow Fever 
Vaccine Backbone
Yellow fever (YF) is a mosquito-borne flavivirus disease that is has long endangered 
persons in sub-Saharan Africa and tropical areas in South America and is associated with a 
case fatality rate of 20–50%(15). Since no effective anti-yellow fever virus medications are 
available and current mosquito-control measures are inadequate, vaccination remains 
paramount to YF prevention and control. Although appropriately controlled efficacy studies 
have never been carried out, the decline in YF cases following vaccination campaigns and 
the production in most studies of neutralizing antibodies in more than 95% of vaccinees are 
considered sufficient evidence that the 17D vaccine is effective. Regulations call for the 
vaccine to be administered every ten years; however, a recent recommendation by WHO’s 
Strategic Advisory Group is that the vaccine need only be given once(16).
The live, attenuated YF 17D vaccine was previously deemed to be the world’s safest and a 
model for the development of other live virus vaccines including polio, measles, mumps and 
varicella. Consequently live vaccines against other flaviviruses, such as Japanese 
encephalitis virus, West Nile virus, and the four serotypes of dengue viruses, based on the 
YF 17D virus vaccine began to be developed. In 2001, however, severe rare reactions that 
were frequently fatal became recognized(17–19). These reactions involved multiple organ 
systems and were named yellow fever vaccine-associated viscerotropic disease (YEL-
AVD). As a consequence, in addition to live virus vaccines, inactivated vaccines, including 
one for YF, are being developed.
Risk groups for the development of YEL-AVD include elderly males as young as 56 
years(20), women in their prime child-bearing years(21), and persons thymectomized as 
treatment for thymoma(22). Guidelines for the definition of viscerotropic disease and for the 
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association of YF vaccine with viscerotropic disease have been developed by a Brighton 
Collaboration working group(23). In addition to YEL-AVD, other rare vaccine reactions 
include anaphylaxis and neurological disease called YF vaccine-associated neurological 
disease (YEL-AND). These reactions are rarely fatal or result in long term sequelae. 
Recognition of YEL-AVD has had a number of consequences including changes in 
recommendations for the vaccination of prospective travelers to and inhabitants in jungle 
(sylvatic) or savanna (intermediate) regions where they have a risk of exposure to YF virus-
infected mosquitoes.
The feared complication of YF is spread of the virus to urban areas where the principal 
mosquito vector is Aedes aegypti, a mosquito that has become difficult if not impossible to 
eradicate in areas of huge tropical and subtropical municipalities with their large urban 
slums. Strategies for vaccination have also become complex as the number of cases of YEL-
AVD in travelers have exceeded the number of cases of YF(15). In South America, during 
periods of low virus activity, the risk to travelers of serious adverse events from the vaccine, 
particularly males over the age of 60, may be similar to that of developing yellow fever. In 
contrast, in Africa, the risk of acquiring yellow fever can be 600 times, and of death 700 
times, the risk of vaccination.
An understanding of the makeup of the flavivirus genome is helpful in understanding the 
new vaccines being developed based upon the yellow fever vaccine virus as a vector. 
Flaviviruses are single stranded, positive sense RNA viruses. Their genomes encode three 
structural genes (capsid [C], pre-membrane [prM], envelope [E]) and at least seven non-
structural genes (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5) in that order(24). The 
coding region is flanked by non-coding regions at the 5’ and 3’ ends of the genome. The YF 
17D vaccine was developed by serial passage of a wild-type virus in chicken embryo 
cultures resulting in the acquisition of nucleotide mutations some of which do not cause 
changes in the translated amino acids (synonymous) and some of which do (non-
synonymous). In the YF-17D vectored vaccines that are being developed for Japanese 
encephalitis, West Nile and the four serotypes of dengue viruses, the coding regions of the 
prM-E proteins of the corresponding viruses are substituted for those in the YF 17D virus 
vaccine, resulting in a chimeric virus. The YF-17D viral genome excluding the prM-E genes 
is referred to as the “backbone”. Although the production of such chimeric viruses alone 
may decrease their virulence, preclinical studies have demonstrated that the YF backbone 
has sufficient mutations by itself to maintain vaccine attenuation of chimeric vaccines 
bearing the dengue surface antigens [22]. Another aspect of the chimeric flavivirus 
technology that is distinguished from other viral vectors, is that anti-vector immunity is not a 
significant problem for flavivirus vaccine development. This feature is due to the fact that 
the prM-E region is solely responsible for generating epitopes recognized by neutralizing 
antibodies. Thus, the chimeric vector contains the only neutralizing antigens of the intended 
target for immunization. Previous immunization with YF17D and T cell responses to the YF 
17D backbone are insufficient to prevent effective immunization with a chimeric vector 
expressing a heterologous flavivirus prM-E transgene.
The efforts of the V3SWG were focused initially on the above flavivirus vaccines. Not 
addressed are additional possible vaccines in which nucleotide sequences encoding for 
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epitopes of other micro-organisms might be added into the complete YF virus vaccine 
yielding live virus vaccines with additional vaccination potential. Vaccines employing other 
methods of attenuating flaviviruses through mechanisms such as nucleotide deletions and 
which do not involve a viral vector are not considered in this project(25).
The chimeric vaccines indicated for the prevention of dengue, Japanese encephalitis, and 
West Nile will be considered new entities from the regulatory perspective, and will need to 
be independently assessed for safety and efficacy. However, in the development of these 
new vaccines, the parental YF 17D vaccine virus has provided an important comparator and 
benchmark in all preclinical and many clinical trials. For example, the monkey 
neurovirulence test is an important measure of safety of YF 17D vaccines, and YF 17D was 
used as the reference strain in many studies, which showed that the chimeric vaccines were 
more attenuated than parental YF 17D. An important regulatory question thus arises as to 
whether the age range for vaccination, precautions and contraindications in labelling for use 
of YF 17D vaccines should apply to the new, chimeric vaccines. This question is 
particularly important since data on very rare adverse events will likely not be available at 
the time the new vaccines are approved. The template supplied in this paper contains 
information that can potentially be useful in considering how new chimeric vaccines should 
be described in reference to parental YF 17D vaccines.
1.3 Methods for developing, completing and reviewing the standardized template
Following the process described in the accompanying overview paper(26) as well as on the 
Brighton Collaboration Website (http://cms.brightoncollaboration.org:8080/public/what-we-
do/setting-standards/case-definitions/process.html), the Brighton Collaboration V3SWG was 
formed in October 2008 and includes ~15 members with clinical, academic, public health, 
regulatory and industry backgrounds with appropriate expertise and interest. The 
composition of the working and reference group as well as results of the web-based survey 
completed by the reference group with subsequent discussions in the working group can be 
viewed at http://www.brightoncollaboration.org/internet/en/index/workinggroups.html. The 
workgroup meets via emails and monthly conference calls coordinated by a secretariat 
[currently at CDC’s Division of HIV/AIDS Prevention].
The V3SWG invited a flavivirus expert, Thomas P. Monath (TPM), who has been intimately 
associated with the development of flavivirus vaccines based on the YF virus vaccine 
backbone to complete the template in 2011. The first draft was then critiqued by a member 
of the working group knowledgeable about flaviviruses, Stephen J. Seligman (SJS), 
moderated by another member, James S. Robertson (JSR), discussed by the V3SWG as a 
whole, and then peer reviewed by reference groups (e.g., American Society of Virology, 
American Society of Tropical Medicine and Hygiene) and the Brighton Collaboration 
membership. Bruno Guy updated the template with new information as of October, 2014. 
Sections 8 (Overall Risk Assessment) and 9 (Adverse Effect Assessment) of the Template 
seeks to rate the risk of the viral vector in various situations as: none, minimal, low, 
moderate, high, or unknown. An initial assessment was made by TPM and then reviewed by 
others, based largely on the anticipated frequency and severity of the vaccine adverse event 
versus the expected frequency and severity of the target vaccine preventable disease(15). 
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Depending on the season, the risk of the yellow fever vaccine approaches the risk of YF in 
S. America. In Africa the risk of yellow fever is usually much greater than the risk of the 
vaccine. The V3SWG may develop more explicit criteria for standardizing the rating of 
these risks in the future with further experience.
The resulting template is submitted as a guideline for evaluating the current issues in 
development of vaccines based on the yellow fever virus vaccine backbone.
2. Standardized template (Table 1)
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Table 1
Risk/Benefit Assessment for Live Virus Vaccines Based on a Yellow Fever Vaccine Backbone
1. Basic Information Information
1.1. Author(s) Thomas P. Monath MD/ modified by Stephen J. Seligman MD/ moderated by Jim Robertson 
MD
1.2. Date completed/updated March 1, 2011 (JSR), updated September 25, 2014 (SJS,TPM)
2. Vaccine Vector information Information
2.1. Name of Vaccines Yellow fever 17D-204, Yellow fever 17DD, ChimeriVax-TDV (CYD-TDV), ChimeriVax-JE, 
Imojev®, ChimeriVax WN
2.2. Class/subtype Flaviviridae/Flavivirus single strand positive-sense RNA virus
2.3. Proposed route of administration subcutaneously
3. Characteristics of wild type agent and 
attenuated vaccine derived from them
Information Comments/Concerns Reference(s)
3.1. Disease(s) caused by wild type, the 
strength of evidence, severity, and duration 
of disease for the following categories:
Wild-type yellow fever (YF) virus 
causes hepatitis and hemorrhagic 
fever
Mortality rates of 20– 50% (15)
3.1a. Disease(s) caused by attenuated live 
yellow fever virus vaccine
• Overall Yellow fever vaccine associated 
neurotropic (YEL-AND) and 
viscerotropic (YEL- AVD) Serious 
adverse effects
Reporting rate of YEL- AND is 
0.8 per 100,000 overall. 
According to VAERS data, 
reporting rate of YEL-AVD is 0.4 
per 100,000 overall. Other 
estimates vary widely. Risk for 
YEL- AVD increases in males 
with age ≥56.
In 2001, a series of reports 
appeared in Lancet describing 
severe, frequently fatal, 
viscerotropic reactions to yellow 
fever vaccine that stimulated 
surveillance of what had been 
considered the safest of live virus 
vaccines. Additional cases of 
YEL-AVD in prospective 
travelers and in inhabitants of 
South America were recognized. 
In S. America the incidence may 
be underestimated because much 
of the vaccine is administered to 
previously vaccinated individuals.
In Peru the incidence of fatal 
reactions in a previously 
unimmunized population 
approached 1 in 10,000.In Africa 
surveillance for AEFI remains 
inadequate, although WHO has 
conducted follow-up for adverse 
events after mass YF vaccine 
campaigns, without definitive 
identification of YEL-AVD.
(17–20, 27–30)
• In immunocompromized Association of thymic disease with 
YEL- AVD.
Thymic disease is a 
contraindication to YF 17D
(22, 29, 31–33)
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Immune deficiency a 
contraindication to YF 17D
One report of YEL- AND (fatal) 
in a patient with HIV/AIDS
Systemic lupus erythematosus on 
corticosteroids
3 fatal cases
No safety issues after 
administration of YF17D in 102 
HIV+ volunteers, although rate of 
serious adverse events of up to 3% 
cannot be excluded
• In neonates, infants, children Age <6 months associated with risk 
of YEL-AND, and is a 
contraindication
Children aged 6–9 months only 
vaccinated under special 
circumstances and on the basis of 
current official. advice
(15, 34)
• During pregnancy and in the 
unborn
Pregnancy a hypothetical 
contraindication. However 
congenital infections very rare and 
no reports of adverse effects on 
fetus.
Two reports of neonates acquiring 
17 D infection and YEL- AND via 
milk from recently vaccinated 
nursing mothers
(15, 35)
• Are there any other susceptible 
populations
Elderly have higher risk of YEL-
AND and elderly males, YEL- 
AVD
Women of prime childbearing age
Reporting rate in persons >70 
approx 2 per 100,000 for both 
YEL-AND and AVD
(20, 21, 27, 36)
• Animals Wild-type YF causes similar 
disease in nonhuman primates 
(NHP), and (adapted strains) in 
hamsters, but is neurotropic (no 
hepatitis) in mice. YF 17D vaccine 
inoculated IC neurotropic/lethal in 
mice and causes self- limited 
encephalitis in monkeys.
YF 17D vaccine is controlled by 
monkey neurovirulence test based 
on scoring inflammatory lesions in 
brain/spinal cord
(15)
3.2. Is there any known evidence of 
neurological or cardiac involvement of the 
wild type agent?
YEL-AND most often caused by 
neuroinvasion of CNS followed by 
acute meninogoencephalitis, 
generally self-limited, rare sequelae. 
Rare except in infants <6 mos.
Wild-type YF does not cause 
encephalitis (though the virus is 
neurovirulent in mice and monkeys 
after intracerebral inoculation).
Wild-type (Wt) virus and YEL-
AVD associated with myocarditis, 
but not a prominent feature
3.3. What is known about the types of 
human cells infected and the receptors 
used in humans and animals?
In humans and NHP, wild-type YF 
infects multiple types of lymphoid 
cells, including DCs and Kupffer 
cells, then spreads to hepatocytes. 
YF 17D infects skin at site of 
inoculation, regional nodes, then 
reticulo- endothelial system (RES) 
and bone marrow.
Wt dengue virus infects a large 
variety of cell types, including 
monocytes, macrophages, DCs and 
possibly endothelial cells Chimeric 
YF/DEN vaccines infect DCs in 
vitro
(37–39)
3.4. Does the agent replicate in the 
nucleus?
No
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3.5. What is the risk of integration into the 
human genome?
None
3.6. Does the agent establish a latent or 
persistent infection?
Persistent YF 17D virus infection of 
experimentally infected monkeys 
reported. No evidence in wild-type 
yellow fever of humans, but not 
specifically studied. One report. of 
RNA genomes of YF 17D in urine 
of humans approx.. 6 mos. after 
vaccination
Chronic infection with West Nile, 
Japanese encephalitis, and TBE 
have been described in animal 
models and in humans
IgM antibody lasting up to 18 
months following 17D vaccination 
in one study suggested the 
possibility of persistent infection.
(40–43)
3.7. How does the wild type agent 
normally transmit?
By agency of blood feeding Aedes 
and spp. Haemagogus mosquitoes
YF 17D vaccine incapable of 
infecting mosquitoes. 
Recombinants produced by the 
insertion of dengue 4, JE and WN 
prM-E genes into wild-type YF 
showed a significant decrease in 
infectivity for mosquito vectors 
compared to wild- type YF.
(15, 44–49)
3.8. What is known about the mechanisms 
of immunity to the wild type agent?
Both wild-type and vaccine induced 
immunity against future or repeated 
infection principally via 
neutralizing antibodies. Innate 
immune responses play an 
important role in early defense. 
CTLs responsible for clearing 
infection and recovery
Defects in innate immunity 
(interferon pathways) may 
underlie susceptibility of rare 
individuals to severe vaccine 
associated SAEs (YEL-AVD).
Interferon receptor k/o mice 
develop viscerotropic disease
(50–52)
3.9. Is there treatment required and readily 
available for the disease caused by the 
wild type agent?
No. See cited review (53)
Characteristics of proposed chimeric 
vaccines
Information Comments/ Concerns Reference(s)
4.1. What is the basis of attenuation/
inactivation?
Chimerization (replacement of 
structural membrane and envelope 
genes (prM-E) with genes from 
another Flavivirus).
Evidence that chimerization itself 
contributes to attenuation also 
comes from experiments showing 
that insertion of prM- E genes from 
wt DENV 4 in a wt YF Asibi 
backbone results in decreased 
virulence
(39, 54–57)
Multiple mutations in the YF 17D 
non- structural genes that occurred 
during empirical passage to develop 
the attenuated 17D vaccine
(58)
In some vaccine constructs, 
mutations were also inserted in the 
prM-E genes of the gene donor 
virus to decrease neurovirulence 
(WN vaccine). For constructing the 
chimeric JE vaccine, prM-E genes 
from the attenuated SA1414.2 
vaccine were used, already 
containing some mutations as 
compared to wt JE virus
4.2. What is the risk of reversion to 
virulence or recombination with wild type 
or other agents?
Negligible due to replacement of 
entire PrM-E gene (chimerization), 
Attenuated YF 17D and 17DD 
vaccines differ from wild-type YF 
in the genes encoding 20 amino 
(44, 56, 59–63)
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redundant mutations. See discussion 
of recombination in reference cited
acids. In addition there are 4 nt 
changes in the 3’UTR that also 
might affect attenuation. The prM-
E sequences in the YF vaccine 
result in 8 amino acid changes. 
Accordingly, the chimeric 
vaccines lack the mutations in the 
prM-E genes of 17D virus. 
Evaluation of chimeric vaccine 
candidates versus parental YF 
17D with respect to markers of 
attenuation in vitro and in vivo 
have consistently shown that the 
chimeric viruses are more 
attenuated than the parent. More 
than 29,000 humans subjects have 
received ChimeriVax vaccines 
without significant safety issues.
Empirical studies have been 
performed to assess the biological 
consequences of non- homologous 
recombination of the chimeric 
vaccine viruses with prM-E or 
backbone sequences from virulent 
flaviviruses. These studies have 
shown that such recombinational 
events do not result in restoration 
of a virulent phenotype or a virus 
that has increased potential to 
disseminate via mosquito bite.
4.3 Are yellow fever virus and chimeric 
viruses derived from them genetically 
stable?
YF 17D vaccine is an uncloned 
mixture (genetic swarm) as shown 
for all other flaviviruses. The 17D 
vaccine contains multiple diverse 
plaque populations and 
subpopulations of virions that react 
with wild-type specific YF 
monoclonal antibodies.
In one fatal case of encephalitis 
caused by YF 17D vaccine, the 
virus isolated from brain contained 
two mutations that were associated 
with increased neurovirulence.
In contrast, 17D isolates from cases 
of YEL- AVD have not shown 
mutations or selection of a specific 
subpopulation or variant associated 
with these adverse events.
Overall, sequencing studies show 
that yellow fever 17D vaccines as 
manufactured using the seed lot 
system, and the chimeric constructs 
derived from them, have 
demonstrated low rates of mutation 
during in vitro and in vivo 
replication.
Furthermore, YF appears to be more 
genetically stable than other RNA 
viruses. This may be due in part to 
the high fidelity of its polymerase
However, 27% of the yellow fever 
fusion peptide sequences deposited 
in GenBank show changes in this 
highly conserved region in contrast 
to 5% of other pathogenic 
flaviviruses suggesting that yellow 
fever virus is not more genetically 
stable than other flaviviruses at least 
in this small region.
(64–72)
4.3a. Are the chimeric vaccine candidates 
genetically stable during multiple 
passages?
Yes All chimeric vaccine candidates 
have been assessed for genetic 
stability through serial passages. 
YF polymerase appears to be quite 
(39, 57, 68, 70)
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stable compared to other RNA 
viruses.
ChimeriVax vaccines have all 
been made by molecular cloning 
and transfection of RNA into 
acceptable cell substrates to 
produce vaccine seed. The 
resulting seed stock is then 
biologically cloned (by plaque 
purification). Molecular and 
biological cloning promote 
genetic homogeneity of the 
vaccine virus. The actual vaccines 
are passed only a few times in cell 
cultures during manufacture. They 
are assessed for genetic stability 
on serial passage; after these 
viruses accumulate a few 
mutations related to adaptation to 
Vero cells, they have been quite 
stable on serial passages. Quality 
control procedures (sequencing) is 
used to monitor genetic stability 
of virus seeds and vaccine lots. 
Specifications for the consensus 
sequence are used for vaccine 
release
4.4. What is known about the genetic 
stability during in vivo replication?
Less empirical information, but no 
indication of instability, reversion to 
virulence.
Serial in vivo passages in mice 
showed no reversion.
(69)
4.5. Will a replication competent agent be 
formed?
The chimeric vaccines are 
replication competent
4.6. What is the potential for shedding and 
transmission?
Considered unlikely, except for 
possible secretion in breast milk
The presence of virus titers as high 
as 6.2×109 genome equivalents/g in 
individuals with YEL- AVD 
increases the possibility of 
transmission.
Chimeric YF/West Nile vaccine 
studied in horses; no evidence for 
shedding but vaccines intended for 
other species may need studies.
Limited persistence and bio-
distribution in monkeys after 
vaccination with Chimerivax- WN
(35, 38, 73, 74)
4.7. Will the agent survive in the 
environment?
No
4.8. Is there a non-human ‘reservoir’? Not for the attenuated vaccine virus
4.9. Is there any evidence for or against 
safety during pregnancy?
See discussion of YF17D vaccine
4.10. Can the vector accommodate 
multigenic inserts or will several vectors 
be required for multigenic vaccines?
See comments Tetravalent YF/dengue vaccine 
required making 4 separate 
vectors and mixing in a 
formulation.
(39, 54)
4.11. What is known about the effect of 
pre-existing immunity on ‘take’, safety or 
efficacy in animal models?
No antivector immunity because 
prM-E (containing neutralizing 
epitopes) of YF replaced by 
corresponding genes of target 
vaccine virus. Prior YF immunity 
does not interfere. T cell responses 
to YF 17D non-structural proteins 
do not preclude effective 
immunization or re-use of vectors.
Positive effect on chimeric dengue 
vaccine immunogenicity due to 
prior 17D immunity
See above reviews
5. Manufacturing Information Comments/ Concerns Reference(s)
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5.1. Describe the source (e.g. isolation, 
synthesis).
Infectious cDNA clone of YF 17D 
vaccine virus Sanofi Pasteur - 
Swiftwater PA
5.2. Describe the provenance of the vector 
including passage history and exposure to 
animal products.
FDA licensed YF 17D vaccine No fetal bovine serum (FBS) or 
animal products used in 
manufacturing process
5.3. Can the vector be produced in an 
acceptable cell substrate?
Yes Vero cells, WHO-87 cells, FDA 
bank deposited at ATCC
5.4. Describe the proposed production 
process.
prM-E of vector replaced with 
corresponding genes of virus 
against which immunity is desired
Chimeric RNA transfected into 
Vero cells to produce chimeric 
live attenuated vaccine
See above reviews
5.5. What are some Purity/Potential 
contaminants?
Virus purified from supernatant 
fluid by depth filtration, 
ultrafiltration, diafiltration
1.6. Is there a large scale manufacturing 
feasibility?
Vaccines already made at 
commercial scale
1.1. Are there any IP issues and is there 
free use of the vector?
Proprietary, vector system is 
covered by multiple patents
IP licensed by Acambis from St 
Louis University and NIH, and 
multiple new patents filed by 
Acambis. Acambis acquired by 
sanofi Pasteur in 2008
6. Toxicology and potency 
(Pharmacology)
Information Comments/ Concerns Reference(s)
6.1. What is known about the replication, 
transmission and pathogenicity in animals?
Multiple Good Laboratory Practice 
(GLP) toxicity studies performed in 
nonhuman primates (NHP) for 
chimeric vaccines against Japanese 
encephalitis, dengue, West Nile. 
The live chimeric viruses replicate 
in mice, hamsters, monkeys, cause 
transient viremia. Neurovirulence 
tests performed in infant mice and 
NHP, using licensed YF 17D 
vaccine as a reference control
In rodents and NHP, the chimeric 
vaccines were significantly less 
virulent than the licensed YF 17D 
vaccine.
(55, 57, 75–77)
6.2. For replicating vectors, has a 
comparative virulence and viral kinetic 
study been conducted in permissive and 
susceptible species? (yes/no) If not, what 
species would be used for such a study? Is 
it feasible to conduct such a study?
Many such studies, see references See above.
(54)
6.3. Does an animal model relevant to 
assess attenuation exist?
Reduced viremia in NHP infected 
with ChimeriVax-DEN vs. Wt DEN 
viruses
For the encephalitides, e.g. JE and 
WN, rodents and NHP are excellent 
models in which to assess 
attenuation of neurovirulence. YF 
17D is neurovirulent (and in infant 
mice neuroinvasive), whereas the 
chimeric vaccines are significantly 
attenuated. Specifications for 
release of seed viruses include 
demonstration of reduced 
neurovirulence in a GLP test in 
NHP.
One of the difficulties in 
developing a dengue vaccine has 
been the absence of a convenient 
animal model. In nonhuman 
primates wild-type dengue causes 
a transient viremia, but no disease. 
A mouse model for dengue has 
been described, but since it 
involves immunocompromized 
mice, it can’t be used to evaluate 
vaccine efficacy.
See above.
(54, 57, 75, 78)
6.4. Does an animal model for safety 
including immuno- compromised animals 
exist?
Unpublished studies in hamsters 
treated with cyclophosphamide 
showed no increase in virulence 
(57, 79)
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except for prolonged subclinical 
viremia.
Chimeric JE vaccine was fully 
attenuated in type I/II IFN receptor 
KO mice (A129 or AG129)
6.5. Does an animal model for 
reproductive toxicity exist?
Yes, but not tested Ongoing for chimeric dengue 
vaccine
6.6. Does an animal model for 
immunogenicity and efficacy exists?
Hamsters, mice, horses, monkeys See references and reviews (80)
6.7. What is known about biodistribution? Replicates in skin at site of 
inoculation, then draining nodes, 
then RES and bone marrow.
Virus cleared after adaptive 
immunity established
(38)
6.8. Have neurovirulence studies been 
conducted?
Multiple All lots of vaccine tested by 
sensitive neurovirulence test in 
infant mice. GLP neurovirulence 
studies in NHP for all new vaccine 
constructs, using licensed YF 17D 
as reference control
(75)
6.9. What is the evidence that the vaccines 
will generate a beneficial immune 
response in:
• Rodent? Rodents (mice, hamsters) 
immunized with single inoculation 
develop neutralizing antibodies and 
protected against challenge with 
wild-type virus corresponding to the 
inserted prM-E gene
Examples include Japanese 
encephalitis and West Nile
See above.
(54, 57)
• Non rodent? Horses immunized and protected 
against West Nile
Licensed vaccine (Prevenile®, 
Intervet) for horses
(77, 79, 81–84)
• NHP? Multiple studies showing 
immunogenicity and protection 
against challenge with dengue, JE, 
WN
(54, 77, 81, 83)
• Human? The ChimeriVax-JE vaccine 
(Imojev®) was approved in 
Australia, Thailand and other Asian 
countries based on Phase 1– 3 
studies showing non-inferiority of 
neutralizing antibody responses to 
approved JE vaccine. The 
ChimeriVax-WN vaccine has been 
shown to elicit protective levels of 
neutralizing antibodies as well as 
strong T cell responses in Phase 1–2 
clinical trials
A placebo-controlled phase 2b 
study of tetravalent ChimeriVax- 
DEN in Thai children conducted in 
a single site demonstrated 
protection against types 1, 3 and 4 
but, despite the production of 
neutralizing antibodies, there was 
no observed protection from disease 
with type 2 dengue, the most 
prevalent circulating serotype. A 
subsequent phase 3 study in Asian 
children conducted in 5 countries 
and 11 sites found 56% overall 
protection against dengue fever 
(which met the proscribed study 
end- point), however efficacy 
The Thai study of ChimeriVax-
DEN with confirmation from an 
Asian and Latin American study, 
raises the possibility that 
protective efficacy is lower 
against type 2 dengue. However, 
protection against hospitalization 
and severe dengue involved all 4 
serotypes. In the phase 3 studies 
there were no deaths caused by 
dengue in the control or vaccine 
groups. Accordingly the efficacy 
of the vaccine in preventing 
mortality remains to be studied.
(38, 39, 45, 57, 
85–89)
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against dengue 2 was lower than for 
other serotype. 35% protection 
against type 2 dengue was observed, 
compared to 50 to 78% protection 
against the other serotypes Vaccine 
efficacy of against dengue 
hemorrhagic fever (DHF) was 
88.5% (per protocol) and 67.2% 
against hospitalization (intent to 
treat).
A phase 3 study in Latin America 
further confirmed the results 
obtained in Asia, with a 61% 
overall protection against dengue 
fever, with an efficacy of 50% 
against serotype 1, , 42% against 
serotype 2, 74% against serotype 3 
and 77% against serotype 4. A 
significant protection was also 
observed against severe disease and 
hospitalization.
Sanofi Pasteur, 
unpublished data
Multiple previous Phase 2 studies 
also suggested a similar level of 
efficacy
(90)
6.10. Have challenge or efficacy studies 
been conducted with:
• HIV? see 3.1a in immunocompromized
• Other diseases? JE, dengue, WN (see refs)
7. Previous Human Use Please type one of the following: 
Yes, No, Unknown, N/A (non- 
applicable)
Comments Reference(s)
7.1. Has the vector already been used for 
targeting the disease of vector origin 
(measles, BCG, rabies)?
Yes, licensed vaccine against YF
7.2. What is known about the replication, 
transmission and pathogenicity of the 
vector in:
See first section
• healthy people?
• Immunocompromised?
• neonates, infants, children?
• pregnancy and in the unborn?
• gene therapy experiments?
• any other susceptible 
populations?
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7.3. Is there any previous human 
experience with a similar vector including 
in HIV+ (safety and immunogenicity 
records)?
non-applicable
7.4. Is there any previous human 
experience with present vector including 
HIV+ (safety and immunogenicity 
records)?
see 3.1a
7.5. What is known about the effect of pre-
existing immunity on ‘take’, safety or 
efficacy in any human studies with this or 
different insert?
prior administration of 17D does 
not interfere with the chimeric 
vaccines
7.6. Name some other non-HIV vaccines 
using same vector and describe some of 
the public health considerations.
none
8. Overall Risk Assessment Describe the toxicities Please rate the risk as one of the 
following: none, minimal, low, 
moderate, high, or unknown
CommentsReference(s)
8.1. What is the potential for causing 
serious unwanted effects and toxicities in:
• Healthy people? Multiple trials of chimeric YF with 
JE, dengue, WN gene inserts have 
not shown any significant safety 
issues
The chimeric JE vaccine 
(ImoJev®) is licensed, the 
chimeric dengue vaccine is in 
Phase III and the WN vaccine is in 
Phase II. A veterinary vaccine 
against WN is licensed
See 
previo
us and 
(91)
• Immunocompromised? No data
• Neonates, infants, children? Trials of the chimeric JE and 
dengue vaccines have been 
conducted in children 2 years and 
older, and have shown them to be 
safe and well tolerated.
• Pregnancy and in the unborn? No data. Parental YF 17D (and 
therefore ChimeriVax) not be 
administered during pregnancy 
unless clearly required, based on a 
high risk exists of natural infection
• Other susceptible populations?
8.2. What is the risk of neurotoxicity / 
neuroinvasion or cardiac effects?
The vaccines are significantly less 
neurovirulent than the licensed YF 
17D vaccine
(75)
8.3. What is the potential for shedding and 
transmission in risk groups?
YF 17D rarely transmitted to infants 
via breast milk
Viremia titers as high as 6.2×109 
genome equivalents/g in individuals 
dying with YEL-AVD raise the 
possibility of transmission by blood 
but likelihood of adverse event low 
since the virus in such individuals 
has few/no mutations
However, multiple studies have 
shown that the chimeric vaccines 
are not infectious for mosquitoes
(45–49, 74)
8.4. What is the risk of adventitious agent 
(including TSE) contamination?
Minimal. Seed viruses and each 
vaccine lot are tested for 
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adventitious viruses. No animal 
products used in manufacturing.
8.5. Can the vector be manufactured at 
scale in an acceptable process?
Yes, the JE vaccine is at 
commercial scale now; Sanofi 
Pasteur has constructed a 
commercial factory for the dengue 
vaccine
10,000–50,000 doses per L –very 
efficient process
8.6. Can virulence, attenuation and toxicity 
be adequately assessed in preclinical 
models?
Yes
8.7. Rate the evidence that a beneficial 
response will be obtained in humans.
Already known— neutralizing 
antibodies in >95% of human 
subjects. T cell responses to the E 
protein conserved in humans
The dengue vaccine contains a 
mixture of 4 separate viruses each 
representing 1 serotype. 
Interference between the 
individual viruses is observed, so 
that 2-3 doses are required for 
complete immunization. In 
contrast the JE and WN vaccines 
are monovalent and a single dose 
provides durable immunity and T 
cell memory.
The proposed correlate of 
protection for chimeric vaccines 
against encephalitic viruses (JE, 
WN) is the level of neutralizing 
antibodies (PRNT50 titer), and a 
level of >10 is considered 
protective; the chimeric vaccines 
elicit neutralizing antibody titers 
in great excess over this minimum 
protective level. However, an 
immune correlate is not 
established yet for dengue 
vaccines. Cellular immunity may 
also contribute to protection, and 
it has been shown that chimeric 
vaccines are able to induce 
significant responses in this 
respect.
(39, 57, 91–93)
9. Adverse Effect Assessment Describe the adverse effects Please rate the risk as one of the 
following: none, minimal, low, 
moderate, high, or unknown
CommentsReference(s)
9.1. Describe the adverse effects observed
• Mild local reactions Erythema, pain Minimal
• Mild systematic reactions Similar to placebo
• Moderate local reactions Erythema, pain Minimal
• Moderate systematic reactions Similar to placebo
• Severe local reactions None
• Severe systematic reactions None
10. Administration Assessment Information Comments/ Concerns Reference(s)
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10.1. What is the average Tissue Culture 
Infections Dose per millimeter (TCID/ml)?
Human dose is 3–5 log10 plaque 
forming units (PFU).
10.2. What is the highest TCID/ml that can 
be used before cell toxicity?
The viruses cause CPE in vitro at 
low multiplicities of infection 
(MOI).
10.3. Are different demographics affected 
differently?
No information
References Information
Vaccine. Author manuscript; available in PMC 2016 January 01.
